Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Accured Expenses (2023 - 2025)

Immunome's Change in Accured Expenses history spans 3 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 13155.81% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $4.5 million, down 66.55%, while the annual FY2025 figure was $4.5 million, 66.55% down from the prior year.
  • Change in Accured Expenses reached $5.7 million in Q4 2025 per IMNM's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q2 2024 to a low of -$8.5 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is $1.6 million, with a median of $1.0 million recorded in 2023.
  • The largest YoY upside for Change in Accured Expenses was 13155.81% in 2025 against a maximum downside of 1373.69% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $2.1 million in 2023, then plummeted by 97.92% to $43000.0 in 2024, then skyrocketed by 13155.81% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Change in Accured Expenses are $5.7 million (Q4 2025), $6.7 million (Q3 2025), and $619000.0 (Q2 2025).